GlobeNewswire

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
06/11/2026
Bria-OTS+™ demonstrates broad immune activation and sustained cancer-cell killing across multiple tumor models BriaPro data highlights BP-80 tolerability in primates and advances in tumor-targeted checkpoint inhibition [...]
Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates
06/11/2026
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic mechanisms and [...]
Immunocore reports third quarter financial results and provides a business update
06/11/2026
KIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase 3 TEBE-AM trial for [...]
SOTIO Presents Initial Data from VICTORIA-01 Phase 1 Clinical Study of Immunocytokine SOT201 at SITC Annual Meeting
06/11/2026
SOT201, a novel cis-acting immunocytokine, combines IL-15 superagonist and anti-PD-1 activity in order to stimulate tumor specific T cells Data show early evidence of durable antitumor activity with SOT201, including [...]
Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
06/11/2026
CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized by VEGF-A-dependent [...]
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
06/11/2026
Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec (aglatimagene) in localized prostate cancer and non-small cell lung cancer (NSCLC), and for [...]
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
06/11/2026
- Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival extended by 1.8- [...]
Azalea Therapeutics Presents New Preclinical Data at SITC 2026 Highlighting Durable Anti-Tumor Activity and Modular Capabilities of its In Vivo CAR T Cell Platform
06/11/2026
In vivo-engineered TRAC-CAR T cells demonstrate complete leukemia tumor clearance in mice, including following tumor rechallenge without additional dosing Modular platform enables dual-antigen targeting to limit tumor [...]
ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London
06/11/2026
SAN CLEMENTE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will [...]
CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
06/11/2026
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens [...]
Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
06/11/2026
Kristi and Kodi Share Their Experience Living with the Rare Genetic Skin Disease, Alongside Insights from Pediatric Dermatologist Moise Levy, MD Kodi, who lives with Netherton Syndrome, in the latest NETHERTON NOW [...]
BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application
06/11/2026
SUNNYVALE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ: BCDA) , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
OneMedNet Reports Preliminary Revenue for Third Quarter 2026 and Fourth Quarter 2026 Outlook
06/11/2026
MINNEAPOLIS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI [...]
Notification of managers’ transactions
06/11/2026
ANNOUNCEMENT NO. 327 6 November 2026 ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation No. 596/2014 concerning transactions in shares of ChemoMetec A/S carried out by persons [...]
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
06/11/2026
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026 BOND-003 Cohort P and CORE-008 Cohort CX 12-month data [...]
Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference
06/11/2026
PRINCETON, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, will [...]
Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update
06/11/2026
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026 Enrollment in registrational STARBORN-1 trial now expected to complete in early [...]
Curonix Freedom® Peripheral Nerve Stimulator (PNS) System Named Top New Pain Management Technology in Orthopedics This Week's Inaugural 2026 Awards
06/11/2026
POMPANO BEACH, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Curonix, a leading medical technology company dedicated to relieving chronic pain, today announced that the Freedom® Peripheral Nerve Stimulator (PNS) System has [...]
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
06/11/2026
– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Orphan Medicinal Products ( [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum